In­vestors add $17M to Em­u­late Se­ries B as Co­v­ance part­ners; UMass pro­fes­sor to work with Spark on next-gen vec­tors

Em­u­late has topped up its B round with a fresh in­jec­tion of $17 mil­lion, bring­ing the to­tal to $45 mil­lion. The biotech has been de­vel­op­ing or­gans-on-a-chip tech that are be­ing used to sup­ple­ment, and per­haps one day re­place, an­i­mals in pre­clin­i­cal re­search. The big CRO Co­v­ance, mean­while, has signed up to start to in­te­grate Em­u­late’s kid­ney-on-a-chip tech in­to its drug eval­u­a­tion work.

Spark Ther­a­peu­tics is part­ner­ing up with Uni­ver­si­ty of Mass­a­chu­setts Pro­fes­sor Guang­ping Gao to pur­sue next-gen vi­ral vec­tors that can work as bet­ter de­liv­ery ve­hi­cles for fu­ture gene ther­a­pies for the reti­na, liv­er and cen­tral ner­vous sys­tem. “These next-gen­er­a­tion AAV vec­tors, Gao says, will be de­signed to “de­liv­er ge­net­ic in­for­ma­tion to cer­tain cell types more ef­fi­cient­ly and to cell types that are oth­er­wise hard to tar­get.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN